Equities

Paxman AB (publ)

Paxman AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)67.80
  • Today's Change4.80 / 7.62%
  • Shares traded51.94k
  • 1 Year change+113.21%
  • Beta1.0331
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Paxman AB (publ) is a Sweden-based developer of scalp cooling technology. The cooling system aims to reduce the risk of hair loss connected with cytostatic treatment of cancer. The Company offers a stand-alone, mobile electric cooling unit, which markets under the name Paxman Scalp Cooler, which is a liquid-based cooling system that cools down the patients scalp through the silicone hat. The product has two versions - for one or two patients to be cooled at once. Each device contains a built-in touch screen with a menu-controlled graphic user interface to monitor the process. The lightweight system enables patient to participate in other activities. The Company’s primary markets are Great Britain, Scandinavian countries, the Netherlands, Belgium and Australia.

  • Revenue in SEK (TTM)238.86m
  • Net income in SEK28.64m
  • Incorporated2016
  • Employees102.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gentian Diagnostics ASA146.78m2.22m631.69m58.00324.803.9255.744.300.12620.12629.3510.470.77921.698.402,533,190.001.18-10.761.33-11.8651.6941.461.51-26.995.01--0.0394--32.9827.6354.92---4.92--
Omda AS420.67m-25.98m647.42m271.00--10.2422.781.54-1.27-1.2720.923.030.584737.9313.471,447,038.00-3.83-4.92-7.72-6.3793.0790.22-6.55-9.831.150.06810.8875--12.3019.83179.30---3.93--
Senzime AB (publ)55.29m-131.46m649.41m52.00--2.41--11.74-1.09-1.090.45952.380.15331.574.91---36.44-35.69-39.12-38.0033.27-20.59-237.75-558.682.62--0.0739--154.7761.90-1.09---3.69--
ADDvise Group AB (publ)1.63bn114.40m752.08m643.0020.223.053.570.46250.59350.59358.383.930.5658.375.772,606,250.003.983.724.824.7742.0748.957.045.891.402.350.69690.940544.3038.6227.62--30.35--
OssDsign AB127.49m-90.44m776.39m25.00--3.62--6.09-1.00-1.001.352.200.40331.325.962,656,063.00-28.61-37.92-31.51-43.5688.6468.10-70.94-203.065.44-20.450.01--96.8453.26-31.30---56.16--
Optomed Oyj157.57m-69.40m901.75m113.00--3.15--5.72-0.3355-0.33550.7631.260.42671.754.06119,307.00-18.79-12.95-22.82-15.9064.8065.69-44.04-27.842.76-20.420.1313--3.003.4718.84--7.26--
C Rad AB497.02m53.43m913.09m94.0017.533.1014.591.841.581.5814.728.961.235.042.725,712,816.0013.255.0919.167.0246.3043.1210.814.862.32--0.00490.0040.9217.44375.0510.8933.69--
Bactiguard Holding AB254.96m-56.11m1.07bn163.00--3.67--4.19-1.60-1.607.289.370.37063.847.601,174,917.00-8.16-7.56-11.32-8.8147.5347.91-22.01-26.280.5898-2.720.4175---11.966.46-161.71--8.43--
BioPorto A/S54.22m-95.22m1.12bn36.00--8.26--20.62-0.163-0.1630.09390.20140.33763.396.121,126,000.00-59.29-71.10-74.24-96.5570.6263.38-175.62-239.224.91-52.720.0507--6.873.5425.81---51.56--
Paxman AB (publ)238.86m28.64m1.20bn102.0041.918.2125.525.011.501.5012.547.671.312.746.562,624,791.0015.66-5.0820.74-7.7670.2769.3811.99-5.071.9812.730.0838--43.9929.35180.69--6.26--
Sedana Medical AB (publ)174.14m-57.24m1.22bn78.00--1.28--6.99-0.5763-0.57631.759.560.16971.1610.142,204,317.00-5.58-5.77-5.84-6.0870.6064.06-32.87-36.136.02-30.480.0076--25.2321.5918.90--42.12--
Nordhealth As506.12m-95.70m1.68bn403.00--3.3257.593.32-1.23-1.236.5011.210.475--9.491,282,595.00-8.98---10.01--85.89---18.91------0.00--18.60--21.96------
Genovis AB129.73m27.91m1.78bn32.0063.808.0145.4613.730.42630.42631.983.390.4239----3,506,189.009.1218.569.8021.4564.6965.5121.5123.88----0.25550.0054.5435.56449.56--47.59--
Data as of Nov 22 2024. Currency figures normalised to Paxman AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

14.80%Per cent of shares held by top holders
HolderShares% Held
The Bank of New York Mellon Corp. (Investment Management)as of 29 Dec 20231.03m5.43%
Alcur Fonder ABas of 29 Dec 2023674.83k3.55%
L�nsf�rs�kringar Fondf�rvaltning ABas of 29 Dec 2023585.00k3.08%
Andra AP-fondenas of 29 Dec 2023456.62k2.40%
E. �hman J :or Fonder ABas of 31 May 202435.88k0.19%
Alphajet Fair Investors SASas of 12 Nov 202422.24k0.12%
AIFM Capital ABas of 30 Jun 20244.61k0.02%
FCG Fonder ABas of 31 Oct 20243.86k0.02%
More ▼
Data from 30 Jun 2024 - 12 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.